Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

The State Research Center of Virology and Biotechnology “VECTOR” of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in i...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Alexander B. Ryzhikov, Evgeny A. Ryzhikov, Marina P. Bogryantseva, Svetlana V. Usova, Elena A. Nechaeva, Elena D. Danilenko, Stepan A. Pyankov, Andrey S. Gudymo, Anastasiya A. Moiseeva, Galina S. Onkhonova, Oleg V. Pyankov, Ekaterina S. Sleptsova, Nikita V. Lomakin, Veronika S. Vasilyeva, Mikhail V. Tulikov, Vitaly G. Gusarov, Andrey A. Pulin, Maria A. Balalaeva, Svetlana B. Erofeeva, Stanislav A. Terpigorev, Olga A. Rychkova, Ivan M. Petrov, Viktoriia Y. Delian, Vladimir V. Rafalskiy, Sergey V. Tyranovets, Elena V. Gavrilova, Rinat A. Maksyutov
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2023-05-01
سلاسل:	Vaccines
الموضوعات:	SARS-CoV-2 COVID-19 peptide vaccine
الوصول للمادة أونلاين:	https://www.mdpi.com/2076-393X/11/5/998
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!